Description
Zoledronate is a sodium salt form of zoledronic acid. Zoledronic acid is a third generation bisphosphonate that exhibits anti-resorptive, anti-osteoporotic, anti-angiogenic, and anticancer chemotherapeutic activities. In giant cell tumor bone stromal cells, zoledronic acid increases expression of Cbfa-1, osteocalcin, and osterix, inducing apoptosis and osteogenic differentiation; it also inhibits bone resorption and prevents osteoporosis in animal models. In animal models of renal cell carcinoma, zoledronic acid decreases mean vessel density. In breast cancer cells, zoledronic acid reverses the epithelial-to-mesenchymal transition (EMT) by inactivating NF-κB, decreasing self-renewal and cell proliferation. In other cellular models, zoledronic acid inhibits farnesyl diphosphate synthase (FPPS), which results in activation of γδ T cells. Across several breast cancer cell lines, zoledronic acid activates caspases 3, 8, and 9 and decreases expression of Ras and MAPK, resulting in the induction of cell cycle arrest or apoptosis.